Impact of inactivated SARS-CoV-2 vaccination on blastocyst euploidy status: a prospective cohort study of patients undergoing preimplantation genetic testing for aneuploidy in China

Is there a difference in the euploidy status and pregnancy outcomes among patients undergoing preimplantation genetic testing for aneuploidy (PGT-A) inoculated with inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine? From January 2022 to February 2023, patients undergoing the first cycle of PGT-A treatment at the Reproductive Medicine Center of Sichuan Provincial Women’s and Children’s Hospital were prospectively enrolled. The patients were divided into vaccinated group (n = 214) and unvaccinated group (n = 176) based on inoculation of inactivated SARS-CoV-2 vaccines before ovarian stimulation (OS). The primary outcome was euploidy blastocyst rate. The euploidy rate per blastocyst undergone PGT-A (51.14% vs. 55.88%), proportion of cycles with euploidy blastocyst in PGT-A and OS cycles were not significantly different between the vaccinated and unvaccinated groups (P > 0.05). The rates of embryo implantation, clinical pregnancy, spontaneous abortion and live birth, gestational age at delivery, birth weight and height of infants from frozen-thawed embryo transfer (FET) cycle were not significantly different between the two groups (P > 0.05). Inactivated SARS-CoV-2 vaccine may not affect the euploidy status and outcomes of FET among patients undergoing PGT-A. Chinese Clinical Trial Registry. ChiCTR2200055721, https://www.chictr.org.cn/bin/project/edit?pid=148,254, 16 January 2022.